文献速递认知障碍与痴呆神经免疫

提高对快速进展性痴呆中治疗可反应病因的早期识别:STAM3 P评分

Improving Early Recognition of Treatment-Responsive Causes of Rapidly Progressive Dementia: The STAM3 P Score.
PubMed 文献 · Ann Neurol · 2023-10-19

前瞻性观察性研究纳入226例疑似快速进展性痴呆(RPD)成人患者,随访至2年。155例符合RPD标准,其中86例(55.5%)为潜在治疗可反应病因。癫痫发作、肿瘤、磁共振提示自身免疫性脑炎、躁狂、运动异常及脑脊液细胞增多(≥10个细胞/mm3)独立相关,联合起病年龄<50岁构成STAM3 P,捕捉82/86例(95.3%)。

要点

  • STAM3 P特征包括癫痫发作、肿瘤、磁共振提示自身免疫性脑炎、躁狂、运动异常、脑脊液细胞增多(≥10个细胞/mm3)及起病年龄<50岁。
  • STAM3 P特征捕捉82/86例(95.3%)治疗可反应RPD病例。
  • 存在≥3个STAM3 P特征的患者阳性预测值为100%。

核心结论

  • 选定的起病时特征可可靠识别潜在治疗可反应病因的RPD患者。
  • 在临床实践中应用STAM3 P筛查评分可能减少疑似RPD患者的诊断延迟和治疗遗漏。

研究设计与样本

  • 前瞻性观察性研究,纳入226例疑似快速进展性痴呆(RPD)成人患者,随访至2年。
  • 疾病进展采用临床痴呆评定量表总和框评分(Clinical Dementia Rating® Sum-of-Box scores)测量。
  • 采用多变量逻辑回归评估与治疗可反应性相关的临床和辅助检查特征。

主要发现

  • 155例符合RPD标准,其中86例(55.5%)为潜在治疗可反应病因。
  • RPD患者症状发作中位年龄68.9岁(范围22.0-90.7岁),男女数量相似。
  • 控制年龄和性别后,癫痫发作、肿瘤(疾病相关)、磁共振提示自身免疫性脑炎、躁狂、运动异常及脑脊液细胞增多(≥10个细胞/mm3)独立与治疗可反应病因相关。
  • 上述特征联合起病年龄<50岁(即STAM3 P)捕捉82/86例(95.3%)治疗可反应RPD病例。
  • 存在≥3个STAM3 P特征的阳性预测值为100%。

关键数值与推荐

  • STAM3 P特征:癫痫发作、肿瘤(疾病相关)、磁共振提示自身免疫性脑炎、躁狂、运动异常、脑脊液细胞增多(≥10个细胞/mm3)、起病年龄<50岁。
  • 存在≥3个STAM3 P特征阳性预测值为100%。

临床怎么用

  • 作者认为,在临床实践中应用STAM3 P筛查评分可能减少疑似RPD患者的诊断延迟和治疗遗漏。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To improve the timely recognition of patients with treatment-responsive causes of rapidly progressive dementia (RPD). METHODS: A total of 226 adult patients with suspected RPD were enrolled in a prospective observational study and followed for up to 2 years. Diseases associated with RPD were characterized as potentially treatment-responsive or non-responsive, referencing clinical literature. Disease progression was measured using Clinical Dementia Rating® Sum-of-Box scores. Clinical and paraclinical features associated with treatment responsiveness were assessed using multivariable logistic regression. Findings informed the development of a clinical criterion optimized to recognize patients with potentially treatment-responsive causes of RPD early in the diagnostic evaluation. RESULTS: A total of 155 patients met defined RPD criteria, of whom 86 patients (55.5%) had potentially treatment-responsive causes. The median (range) age-at-symptom onset in patients with RPD was 68.9 years (range 22.0-90.7 years), with a similar number of men and women. Seizures, tumor (disease-associated), magnetic resonance imaging suggestive of autoimmune encephalitis, mania, movement abnormalities, and pleocytosis (≥10 cells/mm3 ) in cerebrospinal fluid at presentation were independently associated with treatment-responsive causes of RPD after controlling for age and sex. Those features at presentation, as well as age-at-symptom onset <50 years (ie, STAM3 P), captured 82 of 86 (95.3%) cases of treatment-responsive RPD. The presence of ≥3 STAM3 P features had a positive predictive value of 100%. INTERPRETATION: Selected features at presentation reliably identified patients with potentially treatment-responsive causes of RPD. Adaptation of the STAM3 P screening score in clinical practice may minimize diagnostic delays and missed opportunities for treatment in patients with suspected RPD. ANN NEUROL 2024;95:237-248.

来源:Ann Neurol,查看原文。版权归原作者所有。

引用

  1. Satyadev N, Tipton PW, Martens Y, et al. Improving Early Recognition of Treatment-Responsive Causes of Rapidly Progressive Dementia: The STAM3 P Score. Ann Neurol. 2023. PMID: 37782554. doi:10.1002/ana.26812

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。